Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles

Ryan M. Pearson, Joseph R. Podojil, Lonnie D. Shea, Nicholas J.C. King, Stephen D. Miller, Daniel R. Getts*

*Corresponding author for this work

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Autoimmune diseases, such as celiac disease, multiple sclerosis, and type 1 diabetes, are leading causes of morbidity and mortality in the United States. In these disease states, immune regulatory mechanisms fail that result in T and B cell-mediated destruction of self-tissues. The known role of T cells in mediating autoimmune diseases has led to the emergence of numerous therapies aimed at inactivating T cells, however successful ‘tolerance-inducing’ strategies have not yet emerged for approved standard-of-care clinical use. In this review, we describe relevant examples of antigen-specific tolerance approaches that have been applied in clinical trials for human diseases. Furthermore, we describe the evolution of biomaterial approaches from cell-based therapies to induce immune tolerance with a focus on the Tolerogenic Immune-Modifying nanoParticle (TIMP) platform. The TIMP platform can be designed to treat various autoimmune conditions and is currently in clinical trials testing its ability to reverse celiac disease.

Original languageEnglish (US)
Pages (from-to)282-291
Number of pages10
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume18
DOIs
StatePublished - Jun 2019

Fingerprint

Nanoparticles
Celiac Disease
T-Lymphocytes
Autoimmune Diseases
Clinical Trials
Immune Tolerance
T-cells
Immune System Diseases
Biocompatible Materials
Standard of Care
Cell- and Tissue-Based Therapy
Type 1 Diabetes Mellitus
Multiple Sclerosis
Ability testing
B-Lymphocytes
Morbidity
Antigens
Mortality
Medical problems
Biomaterials

Keywords

  • Allergy
  • Autoimmune disease
  • Clinical trial
  • Drug delivery
  • Immune tolerance
  • Nanoparticle

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

@article{e8269d772729404e937ec35a12cabe90,
title = "Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles",
abstract = "Autoimmune diseases, such as celiac disease, multiple sclerosis, and type 1 diabetes, are leading causes of morbidity and mortality in the United States. In these disease states, immune regulatory mechanisms fail that result in T and B cell-mediated destruction of self-tissues. The known role of T cells in mediating autoimmune diseases has led to the emergence of numerous therapies aimed at inactivating T cells, however successful ‘tolerance-inducing’ strategies have not yet emerged for approved standard-of-care clinical use. In this review, we describe relevant examples of antigen-specific tolerance approaches that have been applied in clinical trials for human diseases. Furthermore, we describe the evolution of biomaterial approaches from cell-based therapies to induce immune tolerance with a focus on the Tolerogenic Immune-Modifying nanoParticle (TIMP) platform. The TIMP platform can be designed to treat various autoimmune conditions and is currently in clinical trials testing its ability to reverse celiac disease.",
keywords = "Allergy, Autoimmune disease, Clinical trial, Drug delivery, Immune tolerance, Nanoparticle",
author = "Pearson, {Ryan M.} and Podojil, {Joseph R.} and Shea, {Lonnie D.} and King, {Nicholas J.C.} and Miller, {Stephen D.} and Getts, {Daniel R.}",
year = "2019",
month = "6",
doi = "10.1016/j.nano.2018.10.001",
language = "English (US)",
volume = "18",
pages = "282--291",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",

}

Overcoming challenges in treating autoimmuntity : Development of tolerogenic immune-modifying nanoparticles. / Pearson, Ryan M.; Podojil, Joseph R.; Shea, Lonnie D.; King, Nicholas J.C.; Miller, Stephen D.; Getts, Daniel R.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 18, 06.2019, p. 282-291.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Overcoming challenges in treating autoimmuntity

T2 - Development of tolerogenic immune-modifying nanoparticles

AU - Pearson, Ryan M.

AU - Podojil, Joseph R.

AU - Shea, Lonnie D.

AU - King, Nicholas J.C.

AU - Miller, Stephen D.

AU - Getts, Daniel R.

PY - 2019/6

Y1 - 2019/6

N2 - Autoimmune diseases, such as celiac disease, multiple sclerosis, and type 1 diabetes, are leading causes of morbidity and mortality in the United States. In these disease states, immune regulatory mechanisms fail that result in T and B cell-mediated destruction of self-tissues. The known role of T cells in mediating autoimmune diseases has led to the emergence of numerous therapies aimed at inactivating T cells, however successful ‘tolerance-inducing’ strategies have not yet emerged for approved standard-of-care clinical use. In this review, we describe relevant examples of antigen-specific tolerance approaches that have been applied in clinical trials for human diseases. Furthermore, we describe the evolution of biomaterial approaches from cell-based therapies to induce immune tolerance with a focus on the Tolerogenic Immune-Modifying nanoParticle (TIMP) platform. The TIMP platform can be designed to treat various autoimmune conditions and is currently in clinical trials testing its ability to reverse celiac disease.

AB - Autoimmune diseases, such as celiac disease, multiple sclerosis, and type 1 diabetes, are leading causes of morbidity and mortality in the United States. In these disease states, immune regulatory mechanisms fail that result in T and B cell-mediated destruction of self-tissues. The known role of T cells in mediating autoimmune diseases has led to the emergence of numerous therapies aimed at inactivating T cells, however successful ‘tolerance-inducing’ strategies have not yet emerged for approved standard-of-care clinical use. In this review, we describe relevant examples of antigen-specific tolerance approaches that have been applied in clinical trials for human diseases. Furthermore, we describe the evolution of biomaterial approaches from cell-based therapies to induce immune tolerance with a focus on the Tolerogenic Immune-Modifying nanoParticle (TIMP) platform. The TIMP platform can be designed to treat various autoimmune conditions and is currently in clinical trials testing its ability to reverse celiac disease.

KW - Allergy

KW - Autoimmune disease

KW - Clinical trial

KW - Drug delivery

KW - Immune tolerance

KW - Nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=85058060972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058060972&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2018.10.001

DO - 10.1016/j.nano.2018.10.001

M3 - Review article

C2 - 30352312

AN - SCOPUS:85058060972

VL - 18

SP - 282

EP - 291

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

ER -